Patent intelligence · US
US 11203602
Thioester prodrugs of macrocycles as inhibitors of histone deacetylases
Thioester prodrugs of macrocycles as inhibitors of histone deacetylases
Patent details — US 11203602
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 21, 2021
- Expiration
- Dec 16, 2041
- Applicant
- OnKure, Inc.
- Claims
- 14
- CPC classes
- A61K, A61K38/15, A61K45/06, A61P
Quick answer
US 11203602 (Thioester prodrugs of macrocycles as inhibitors of histone deacetylases) is held by OnKure, Inc.. Status: granted. Granted Dec 21, 2021. Expires Dec 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- OnKure, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K38/15, A61K45/06, A61P, A61P25/00, A61P29/00
More from OnKure, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12252511
Process for the preparation of cyclic depsipeptides
granted -
US 11739123
Process for the preparation of cyclic depsipeptides
granted -
US 11339150
Benzimidazole compounds as HDAC6 inhibitors
granted -
US 11053284
Process for the preparation of cyclic depsipeptides
granted -
US 10689419
Process for the preparation of cyclic depsipeptides
granted -
US 10100089
Process for the preparation of cyclic depsipeptides
granted
Frequently asked questions
What is US patent 11203602?
US 11203602 (Thioester prodrugs of macrocycles as inhibitors of histone deacetylases) is held by OnKure, Inc.. Status: granted. Granted Dec 21, 2021. Expires Dec 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11203602?
OnKure, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11203602 expire?
Our index shows an expiration date of Dec 16, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.